Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS malignancy consortium protocol 042 Academic Article uri icon

Overview

MeSH Major

  • AIDS-Related Opportunistic Infections
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sarcoma, Kaposi

abstract

  • Imatinib has activity in AIDS-KS. Pharmacokinetic interactions with antiretroviral drugs did not correlate with toxicity. Thirty percent of patients showed long-term clinical benefit and remained on imatinib for the entire year. These results suggest imatinib is well tolerated and may be an alternative therapy for some patients with AIDS-KS.

publication date

  • February 10, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3912327

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.48.6365

PubMed ID

  • 24378417

Additional Document Info

start page

  • 402

end page

  • 8

volume

  • 32

number

  • 5